Consensus statement for the treatment of infantile haemangiomas with propranolol

Australas J Dermatol. 2017 May;58(2):155-159. doi: 10.1111/ajd.12600. Epub 2017 Mar 1.


Although most infantile haemangiomas do not require treatment due to a natural history of spontaneous involution, some require early intervention. The Australasian Vascular Anomalies Network and the Australasian Paediatric Dermatology Network have developed a consensus statement for the treatment of infantile haemangiomas with oral propranolol. Infants with haemangiomas that are life threatening, at risk of ulceration, or at risk of causing a significant functional impairment, psychological impact or physical deformity should be treated early with oral propranolol. Oral propranolol is safe and effective and in most healthy infants oral propranolol can be started in an outpatient setting.

Keywords: Australian; New Zealand; beta-blocker; consensus; hemangioma; infantile haemangioma; propranolol; vascular anomaly.

MeSH terms

  • Consensus*
  • Drug Monitoring
  • Hemangioma, Capillary / drug therapy*
  • Humans
  • Neoplastic Syndromes, Hereditary / drug therapy*
  • Patient Selection
  • Propranolol / administration & dosage
  • Propranolol / therapeutic use*
  • Vasodilator Agents / administration & dosage
  • Vasodilator Agents / therapeutic use*


  • Vasodilator Agents
  • Propranolol

Supplementary concepts

  • Hemangioma, capillary infantile